XML 136 R97.htm IDEA: XBRL DOCUMENT v3.21.1
Shareholders' equity (deficit) - Additional Information (Detail)
12 Months Ended
Jun. 30, 2020
EUR (€)
Dec. 31, 2020
EUR (€)
€ / shares
shares
Dec. 31, 2020
$ / shares
Jul. 01, 2020
EUR (€)
€ / shares
shares
Dec. 31, 2019
EUR (€)
€ / shares
shares
Dec. 31, 2019
$ / shares
Dec. 31, 2018
EUR (€)
Disclosure of classes of share capital [line items]              
Stock issued during period, value, new issues | € € 500,000 € 0.01          
Number of shares outstanding | shares   62,908,617          
Par value per share | € / shares   € 0.01          
Number of shares value outstanding | €   € 629,000   € 629,000 € 1,164,000 [1]    
Share premium | €   € 573,339,000     € 190,945,000 [1]    
Reorganization [Member]              
Disclosure of classes of share capital [line items]              
Number of shares outstanding | shares         33,093,838    
Par value per share | $ / shares           $ 0.01  
ARYA Merger [Member]              
Disclosure of classes of share capital [line items]              
Number of warrants outsatnding | shares   7,187,500          
Exercise price per share | $ / shares     $ 11.50        
Class of warrant or right, term period   5 years          
Immatics Biotechnologies GmbH [Member]              
Disclosure of classes of share capital [line items]              
Number of shares outstanding | shares         1,163,625    
Par value per share | € / shares         € 1.00    
PIPE Financing [member] | ARYA Merger [Member]              
Disclosure of classes of share capital [line items]              
Share premium | €       € 3,625,000,000      
Ordinary Shares [member]              
Disclosure of classes of share capital [line items]              
Number of shares outstanding | shares       62,908,617      
Par value per share | € / shares       € 0.01      
Series E Share Capital [member] | Immatics Biotechnologies GmbH [Member]              
Disclosure of classes of share capital [line items]              
Share premium | €             € 23,600,000
[1] See Note 2 for details regarding the change in presentation of Other financial assets